BioCentury
ARTICLE | Company News

Isis Pharmaceuticals, Regulus Therapeutics LLC, Rosetta Genomics deal

September 29, 2008 7:00 AM UTC

Isis transferred to Regulus a 2006 partnership with Rosetta to discover and develop antisense candidates that regulate microRNAs to treat hepatocellular carcinoma. Regulus, a JV between Alnylam Pharm...